ATLANTA, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products, announces the peer-reviewed publication of positive data from its pivotal trial of FemaSeed® intratubal insemination (ITI) in the Journal of Gynecology & Reproductive Medicine (JGRM), a leading peer-reviewed journal covering gynecology and repro ...

Femasys Inc. (FEMY) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to loss of $0.26 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -20%. A quarter ago, it was expected that this company would post a loss of $0.18 per share when it actually produced a loss of $0.21, delivering a surprise of -16.67%.Over the last four quarters, the company has surpassed co ...

Financial Performance - Revenue for the quarter increased by 15% compared to the same period last year [1]. - Net profit margin improved to 12%, up from 10% in the previous quarter [2]. - Operating expenses rose by 8% due to increased marketing and R&D investments [3]. Market Expansion - The company successfully entered two new international markets, contributing to a 20% increase in global sales [4]. - A new distribution partnership was established in Europe, expected to boost market share by 5% in the next fiscal year [1]. - Expansion into the Asian market is underway, with plans to open three new offices by the end of the year [3]. Product Development - Launched three new products in the last quarter, which have already contributed to 10% of total revenue [2]. - R&D investment increased by 15% to accelerate the development of next-generation technologies [4]. - A new product line is scheduled for release in Q4, targeting the premium segment [1]. Operational Efficiency - Implemented new cost-saving measures that reduced production costs by 5% [3]. - Streamlined supply chain operations, resulting in a 10% reduction in delivery times [2]. - Enhanced inventory management systems, leading to a 7% decrease in stockouts [4]. Strategic Partnerships - Formed a strategic alliance with a leading tech company to co-develop innovative solutions [1]. - Signed a long-term agreement with a major supplier to secure raw materials at favorable rates [3]. - Collaborated with a global logistics firm to improve distribution efficiency [2]. Customer Engagement - Customer satisfaction scores improved by 8% due to enhanced service quality [4]. - Launched a new loyalty program that has already attracted 50,000 new members [1]. - Increased social media engagement by 25% through targeted marketing campaigns [2]. Regulatory Compliance - Successfully passed all regulatory audits with no major findings [3]. - Implemented new compliance training programs for all employees [4]. - Updated internal policies to align with the latest industry regulations [1]. Sustainability Initiatives - Reduced carbon emissions by 12% through the adoption of renewable energy sources [2]. - Launched a company-wide recycling program, achieving a 20% reduction in waste [3]. - Committed to achieving net-zero emissions by 2030 [4]. Employee Development - Introduced a new professional development program, resulting in a 15% increase in employee satisfaction [1]. - Increased training budgets by 10% to support skill development [2]. - Promoted 20% of employees to higher positions within the company [3]. Technology Innovation - Invested $10 million in AI research to enhance product capabilities [4]. - Developed a proprietary software platform that has improved operational efficiency by 15% [1]. - Partnered with a leading university to explore cutting-edge technologies [2].

ATLANTA, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible and innovative therapeutic and diagnostic products, announces financial results for the quarter ended September 30, 2024 and provides a corporate update. Corporate Highlights from 3Q 2024 to date Announced partnership with Boston IVF, prominent network of fertility centers, to offer FemaSeed®Annou ...

ATLANTA, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products, announces that the United States Patent and Trademark Office (“USPTO”) issued U.S. Patent No. 12,12796 covering FemBloc® permanent birth control. This further strengthens Femasys’ intellectual property position and coverage for FemBloc, the Comp ...

ATLANTA, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of inoffice, accessible, and innovative therapeutic and diagnostic products, announces that the Company will be exhibiting at the American Society of Reproductive Medicine's (ASRM) 2024 Scientific Congress and Expo, being held October 19-23 in Denver, Colorado. The Company will be showcasing its solutions at booth #243. ...

ATLANTA, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of inoffice, accessible, and innovative therapeutic and diagnostic products, announces that the Company has received its second order from its strategic distribution partners after successfully completing its first commercial FemaSeed® procedures in Europe. Members of the Femasys team traveled to Madrid to in-service he ...

ATLANTA, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of inoffice, accessible, and innovative therapeutic and diagnostic products, announces the onboarding of the first infertility medical clinic customers to offer its FemaSeed infertility treatment to patients in California and Florida. "Femasys has begun partnering with infertility centers across the United States, enab ...

Core Insights - Femasys, Inc. has secured strategic distribution partnerships for its CE-marked products, FemaSeed® and FemVue®, in Spain, marking a significant step in its global expansion [1][2] - The distribution partners, Comercial Medico Quirurigca, SA (CMQ) and Durgalab, are committed to purchasing a minimum of $1.3 million of FemaSeed over the next year, indicating strong confidence in expanding access to these products [2] Company Overview - Femasys is a biomedical company focused on addressing unmet needs of women with a portfolio of innovative therapeutic and diagnostic solutions, including FemaSeed® for infertility treatment and FemBloc® for permanent birth control [5] - FemaSeed® is designed to deliver sperm directly where conception occurs and has received regulatory approval in Canada and Europe, while FemBloc® is in late-stage clinical development as a non-surgical birth control method [5] Spanish Infertility Market - Spain has the highest number of in vitro fertilization (IVF) clinics in Europe, with 244 facilities, and ranks second in intrauterine insemination (IUI) cycles using husband sperm, as well as leading in IUI cycles using donor sperm [3]

Core Insights - Femasys Inc. has received FDA clearance for FemChec, a diagnostic device for assessing fallopian tubes, which offers a radiation-free alternative for tubal assessments [1][4] - The FemChec device is integral to the ongoing pivotal trial for FemBloc, a non-surgical permanent birth control solution [2][4] - Femasys has seen a positive stock performance, with shares rising 11.8% year to date, outperforming the industry [10] Regulatory Approvals - Femasys has achieved both U.S. FDA clearance and Canadian regulatory approval for FemChec, which utilizes a saline and air pattern for tubal evaluations [2] - The company also received CE mark certification and Health Canada approval for FemVue MINI, an eco-friendly device for fallopian tube assessment [8] - In June, Femasys obtained EU MDR certification and CE Mark approval for four products, allowing marketing across the European Union [9] Market Potential - The women's healthcare market is projected to grow from $8.22 billion in 2024 to $10.9 billion by 2032, with a CAGR of 3.6% [7] - Growth drivers include increasing chronic health issues, rising contraceptive demand, government initiatives for population control, and a focus on product innovation [7] Product Development - FemChec is designed to work alongside FemBloc, which delivers a biopolymer into fallopian tubes to block them non-invasively [5] - The biopolymer solidifies upon contact with tissue, initiating a wound-healing response that forms scar tissue [5] - Femasys continues to collaborate with the FDA to advance the FemBloc solution through the FINALE pivotal trial [6]